Corporate Patrons

Abbott Laboratories is a diversified health care company that discovers, develops, manufactures and markets innovative products and services that span the continuum of care from prevention and diagnosis to treatment and care. Abbott helps people around the world in more than 130 countries.

Affymax is a biopharmaceutical company creating novel approaches for improving patient care for serious and life-threatening conditions in kidney disease and cancer. The company is building a pipeline of drugs against clinically validated targets that Affymax believes will demonstrate significant advantages over currently marketed protein products. 

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

American Access Care is a management company operating freestanding interventional radiology centers primarily dedicated to the care of dialysis patient’s vascular access needs. Our philosophy is to provide optimal patient outcomes while providing the best possible service, and our physicians are committed to improving the standard of care and quality of life for hemodialysis patients. 

American Regent, Inc., manufactures of Venofer® (iron sucrose injection, USP). American Regent’s quality services to the renal community include a clinical support team of nephrology specialists, a professional Speakers Bureau, patient education materials, regional Iron and Anemia Workshops, and a Venofer® Patient Assistance Program and Reimbursement Hotline. To learn more about Venofer®, please visit www.venofer.com.

Amgen develops and delivers important, cost-effective therapeutics based on advances in cellular and molecular biology. For more than 25 years, the company has tapped the power of scientific discovery and innovation to advance the practice of medicine. Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.

Bard Peripheral Vascular, Inc. provides a comprehensive range of interventional and surgical medical devices for the treatment and/or diagnosis of peripheral vascular disease, venous disease, and dialysis access and maintenance. Featured Interventional products include the G2® and G2® X Vena Cava Filter Systems, Simon Nitinol® Filter, Flair™ Endovascular Stent Graft, E-Luminexx® Vascular Stent, E-Luminexx® Biliary Stent, LifeStent® Vascular Stent System, LifeStent® Biliary Stent System, Fluency® Plus Tracheobronchial Stent Graft, Dorado® PTA Balloon Catheter which is now available in lengths up to 20 cm, Conquest® PTA Balloon Catheter, Atlas® Large Diameter PTA Dilatation Catheter.

Baxter is a leading global manufacturer of a complete and complementary portfolio of dialysis-related products and services designed to assist patients with kidney disease throughout the continuum of their care. For nearly 50 years, Baxter has been at the forefront of innovation in kidney care. In 1956, the company introduced the first disposable coil dialyzer, a development that greatly enhanced the use and application of hemodialysis. Years later, Baxter was the first company to introduce peritoneal dialysis products, and the company continues to support the care of people with kidney disease around the world.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

As the industry leader in renal dialysis billing, Brandywine Medical Management Services Incorporated provides A/R liquidation and consulting services to renal dialysis providers nationwide. Brandywine Medical Management Services Incorporated offers new and creative business office solutions to maximize reimbursement, improve process deficiencies, increase operating margin and ensure sound fiscal health.

Our innovative approach to A/R management and advanced technology provides the necessary experience and support to keep current with the latest changes in reimbursement policies and procedures when faced with the difficult challenges of billing and collecting for renal services.  Brandywine Medical Management Services Incorporated remains attuned to the needs and interests of nephrologists and outpatient kidney dialysis treatment centers committed to high quality health care for patients.

Centocor Ortho Biotech Inc. redefines the standard of care in immunology, nephrology and oncology. The company was formed when Centocor, Inc. and Ortho Biotech Inc. were consolidated in late 2008, and was renamed Centocor Ortho Biotech Inc. Built upon a pioneering history, Centocor Ortho Biotech Inc. harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates and healthcare professionals have access to the latest treatment information, support services and quality care. For more information about Centocor Ortho Biotech, visit www.centocororthobiotech.com.

Genzyme, a global health care company, delivers innovative biotechnology products and services in therapeutics, surgery and diagnostic areas. Genzyme is the manufacturer of Renagel® (sevelamer hydrochloride) and Hectorol® (doxercalciferol). Genzyme is a leader in health care awareness and education for renal care specialists and patients worldwide. For more information visit www.genzyme.com or call 1.800.847.0069

Hemosphere, Inc. is leading innovation for hemodialysis patients with compromised vasculature. The HeRO® graft, a novel device, maintains long-term vascular access for ESRD patients who have exhausted sites suitable for fistulas or grafts. HeRO is proven to reduce infections and decrease costs compared to dialysis catheters.

Lifeline Vascular Access develops and manages a nationwide network of dedicated access centers that are committed to delivering improved clinical outcomes and quality of life for patients through optimized vascular access care standards. Lifeline Vascular Access helps reduce missed dialysis treatments and eliminates communication gaps, inconsistent care and long waits for access care while improving patient outcomes and reducing related medical costs.

Medcomp® is the premier developer, manufacturer and supporter of cutting-edge vascular access devices that meet and exceed the clinical demands of today's medical specialties, particularly in the fields of interventional medicine and dialysis.

NxStage Medical, Inc. is a medical device company that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, acute kidney failure and fluid overload. Our primary product is the NxStage System One, a compact, portable hemodialysis machine cleared by the FDA for use in the home and acute settings. Through our Medisystems brand, we also manufacture and sell needles and blood tubing sets in the acute and chronic settings.

Redsense Medical is a medical device company which develops, manufactures and markets the Redsense blood loss monitoring device. The company was founded in 2006 and today markets the Redsense device globally. Redsense is the only FDA cleared device designed to monitor the venous needle during hemodialysis. The Redsense device uses advanced technology in an easy to use application in order to detect blood loss during hemodialysis.

For more information please visit our web site: www.redsensemedical.com

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Starting January 1, 2010, sanofi-aventis U.S. assumes full commercial responsibility for Ferrlecit (sodium ferric gluconate complex in sucrose injection). As the original developer and manufacturer of Ferrlecit, sanofi-aventis is proud to continue to make this important medicine available to the nephrology community. 
 

Watson Pharmaceuticals, Inc., is a specialty pharmaceutical company that develops, manufactures and markets a wide range of brand and generic pharmaceutical products. Watson Nephrology, marketers of FerrlecitR (sodium ferric gluconate complex in sucrose injection), offers specialty products for patients with kidney disease, including injectable iron therapy, oral iron supplements and renal vitamin formulations. Watson Nephrology demonstrates their commitment to the nephrology community through anemia educational programs and support of national nephrology organizations.